Do ACEI/ARB and beta-blocker therapies prevent cardiotoxicity in breast cancer patients treated with antineoplastic agents compared to placebo?
ACEI/ARB and beta-blocker treatments protect against cardiotoxicity in breast cancer patients receiving trastuzumab and anthracycline-containing medications.
= 88.6%, p = 0.000; SMD 0.556, 95% CI 0.299 to 0.813). In an exploratory subgroup analysis, the benefit of experimental agents on LVEF, whether anthracyclines or trastuzumab, was prominent in patients treated with ACEIs, ARBs, and BBs. Compared to placebo, ACEI/ARB and BB treatments in breast cancer patients protect against cardiotoxicity after trastuzumab and anthracycline-containing medication treatment, indicating a benefit for both.
Gao et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: